Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/38724
Title: A long‐term follow‐up of early breast cancer patients treated with photobiomodulation during conventional fractionation radiotherapy in the prevention of acute radiation dermatitis
Authors: ROBIJNS, Jolien 
LODEWIJCKX, Joy 
CLAES, Marithe 
Lenaerts, Melissa
Van Bever, Leen
Claes, Stefan
Pannekoeke, Luc
Verboven, Katleen
Noé, Leen
MAES, Annelies 
BULENS, Paul 
MEBIS, Jeroen 
Issue Date: 2022
Publisher: 
Source: LASERS IN SURGERY AND MEDICINE,
Status: In press
Abstract: Objectives: The evidence demonstrating the efcacy of photobiomodulation (PBM) therapy for preventing and managing acute radiation dermatitis (ARD) is growing steadily. The question that arises from many clinicians is, if PBM is safe for oncologic patients. This study aimed to evaluate the diseasefree survival (DFS), cancerfree survival (CFS), and overall survival (OS) of breast cancer patients treated with PBM for ARD. Methods: Clinical data of 120 breast cancer patients treated with prophylactic PBM (n = 60, 2x/week, 808−905 nm, 4 J/cm 2) or placebo (n = 60) during conventional fractionation (CF) radiotherapy (RT) between April 2015 and June 2017 were retrospectively analyzed (TRANSDERMIS trial). During followup (April 2015 to May 2022), patients underwent a complete clinical evaluation every 6 months and blood analysis and mammography yearly in the rst 5 years after the end of RT. The DFS, CFS, and OS were estimated. Results: At a median followup time of 66 months (range 4−81), there was no signicant difference in DFS (73.7% vs. 98.3%, resp., p = 0.54), CFS (68.4% vs. 77.8%, resp., p = 0.79), and OS (87.9% vs. 98.3%, resp., p = 0.30) between the placebo and PBM group. Conclusions: This paper is the rst to describe the results of a longterm followup in earlystage breast cancer patients who underwent PBM for ARD. Results suggest that using PBM in breast cancer patients undergoing CF RT does not inuence the locoregional recurrence, the development of new primary tumors, or OS.
Keywords: Photobiomodulation;Oncology;Supportive care;PBM;Safety;Follow-up;Cancer
Document URI: http://hdl.handle.net/1942/38724
ISSN: 0196-8092
e-ISSN: 1096-9101
DOI: 10.1002/lsm.23608
ISI #: 000862600000001
Rights: 2022 Wiley Periodicals LLC.
Category: A1
Type: Journal Contribution
Validations: ecoom 2023
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Robijns_2022_safety.pdf
  Restricted Access
Published version422.07 kBAdobe PDFView/Open    Request a copy
Authorversion.pdfNon Peer-reviewed author version657.35 kBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.